Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc.ACXP · Entity 8195 | Director · President and CEO | April 20, 2026 | April 22, 2026 |
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | August 20, 2018 | August 22, 2018 |
| PLx Pharma Inc.PLXP · Entity 129056 | Director | January 17, 2017 | April 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acurx Pharmaceuticals, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2036-04-20 | Direct | 37,100 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,100 · Balance 37,100 F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Enveric Biosciences, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 150,000 |
Reported balance
After 2018-08-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-20 · Grant · Acquired 150,000 · Balance 150,000 F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2018-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-20 · Grant · Acquired 15,000 · Balance 15,000 F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3: The Restricted Stock Units vest on the first anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Direct | 2,430 |
Reported balance
Holding disclosure · report date 2018-08-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,430 |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date.
F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.
F3: The Restricted Stock Units vest on the first anniversary of the grant date.
PLx Pharma Inc.
Report date January 17, 2017 · Filed April 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2022-01-17 | Direct | 275,000 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 275,000 · Balance 275,000 F1: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F2: Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $13.93 · Expires 2019-03-18 | Direct | 0 |
Reported balance
After 2017-04-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-19 · Disposition to issuer · Disposed 298,826 · Balance 0 F1: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F3: Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017.
F2: Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.).
F3: Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 16:17 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 37,100 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001104659-26-046835 · tm2612397-2_4seq1.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock · 37,100 shares Expires 2036-04-20 F1 · derivative.exercise_date: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 17:46 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001104659-25-010180 · tm255798-2_4seq1.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: On February 5, 2025, the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest immediately. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:31 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 49,261 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001104659-25-002052 · tm252665-4_4seq1.xml · derivative · entry 4 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,261 Underlying: Common Stock · 49,261 shares Expires 2030-01-07 F2 · shares: Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:31 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 49,261 | $1.02 | $49,999.92 |
DisclosureSEC source: 0001104659-25-002052 · tm252665-4_4seq1.xml · nonDerivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,097,458 F1 · shares: Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc. Read SEC document |
| February 23, 2024 Filed Apr 3, 2024 21:56 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-24-043293 · tm2411025-2_4seq1.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:24 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | Exercise / conversionWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-24-001373 · tm242052-1_4seq1.xml · derivative · entry 4 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,737 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:24 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | Exercise / conversionCommon Stock | 19,737 | $3.55 | $70,066.35 |
DisclosureSEC source: 0001104659-24-001373 · tm242052-1_4seq1.xml · nonDerivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,048,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2023 Filed Feb 24, 2023 16:31 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 130,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001104659-23-025334 · tm237745-2_4seq1.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 130,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:01 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-22-084315 · tm2222169-1_4seq1.xml · derivative · entry 5 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,737 Underlying: Common Stock · 19,737 shares Expires 2028-01-27 Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:01 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-22-084315 · tm2222169-1_4seq1.xml · derivative · entry 4 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,737 Underlying: Common Stock · 19,737 shares Expires 2024-01-27 Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:01 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 19,737 | $3.80 | $75,000.60 |
DisclosureSEC source: 0001104659-22-084315 · tm2222169-1_4seq1.xml · nonDerivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,460 Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:05 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 5,200 | $4.80 | $24,960.00 |
DisclosureSEC source: 0001104659-21-142471 · tm2133703-1_4seq1.xml · nonDerivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,723 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:06 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001104659-21-089396 · tm2121425-3_4seq1.xml · derivative · entry 2 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-06-30 F2 · derivative.exercise_date: On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's President and Chief Executive Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024. Read SEC document |
| June 29, 2021 Filed Jul 6, 2021 16:06 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 350,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0001104659-21-089396 · tm2121425-3_4seq1.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:08 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-002460 · form410211008luc_082018.xml · derivative · entry 3 LUCI DAVID P · CIK 0001271123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: The Restricted Stock Units vest on the first anniversary of the grant date. F3 · derivative.expiration_date: The Restricted Stock Units vest on the first anniversary of the grant date. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:08 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0000921895-18-002460 · form410211008luc_082018.xml · derivative · entry 2 LUCI DAVID P · CIK 0001271123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_date: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. F1 · derivative.expiration_date: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:30 UTC | PLx Pharma Inc. PLXP · Entity 129056 | Disposition to issuerOptions · Derivative | 298,826 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001144204-17-021599 · v464776_4.xml · derivative · entry 2 LUCI DAVID P · CIK 0001271123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 298,826 shares Expires 2019-03-18 F1 · derivative.exercise_price: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F1 · shares: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F3 · price: Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger. F1 · derivative.underlying_shares: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. Read SEC document |
| January 17, 2017 Filed Apr 21, 2017 21:30 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantOptions · Derivative | 275,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-021599 · v464776_4.xml · derivative · entry 1 LUCI DAVID P · CIK 0001271123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2022-01-17 F1 · derivative.exercise_price: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F1 · shares: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F2 · derivative.exercise_date: Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.). F1 · derivative.underlying_shares: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. F1 · balance_after: Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.